Brief: Sutro Biopharma Reports First Quarter 2023 Financial Results, Business Highlights And Select Anticipated Milestones

Sutro Biopharma

15/05/2023 13:16

Sutro Biopharma Inc  STRO.O :
    * SUTRO BIOPHARMA REPORTS FIRST QUARTER 2023 FINANCIAL
RESULTS,
BUSINESS HIGHLIGHTS AND SELECT ANTICIPATED MILESTONES
    * AS OF MARCH 31, 2023, SUTRO HAD CASH AND INVESTMENTS OF
$251.5
MILLION AND SHARES OF VAXCYTE COMMON STOCK VALUED AT $25.0
MILLION
    * PROJECTED CASH RUNWAY INTO SECOND HALF OF 2024
    * REVENUE WAS $12.7 MILLION FOR QUARTER ENDED MARCH 31,
2023, AS
COMPARED TO $5.9 MILLION FOR SAME PERIOD IN 2022
    * QTRLY LOSS PER SHARE $0.85
    * Q1 EARNINGS PER SHARE VIEW $-0.81 -- REFINITIV IBES DATA

Source text for Eikon:  ID:nGNX7nf0b4 
Further company coverage:  STRO.O